Publications by authors named "Ruxu Jia"
Article Synopsis
- The study investigated the real-world usage of glucagon-like peptide-1 receptor agonists (GLP-1RA) among type 2 diabetes patients in China using data from 18 hospitals between 2016 and 2020.
- Researchers analyzed patient records to assess clinical outcomes and identify factors influencing the use of daily versus weekly GLP-1RA treatments.
- Results showed that both treatment regimens significantly reduced HbA1c levels after 6 and 12 months, with weekly GLP-1RA proving to be more effective, alongside improvements in cholesterol profiles and a reduction in hypoglycemia rates.
Introduction: The efficacy of once-weekly (O.W.) semaglutide for the treatment of type 2 diabetes mellitus (T2DM) has been demonstrated in clinical trials.
View Article and Find Full Text PDFObjective: This study aimed to evaluate the long-term cost-effectiveness of once-weekly subcutaneous semaglutide versus polyethylene glycol loxenatide (PEG-loxenatide) in patients with type 2 diabetes uncontrolled on metformin, from a Chinese healthcare systems perspective.
Methods: The study applied the Swedish Institute of Health Economics Diabetes Cohort Model to evaluate the long-term clinical and economic outcomes of once-weekly treatment of semaglutide at 0.5 mg and 1.